Komentarz: Nowotwór i żylna choroba zakrzepowo-zatorowa - czy zawsze jest to śmiertelna kombinacja Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
maj 31, 2011
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.generic.paperbuzz.metrics##
##plugins.generic.paperbuzz.loading##
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Kurzyna M. Komentarz: Nowotwór i żylna choroba zakrzepowo-zatorowa - czy zawsze jest to śmiertelna kombinacja. OncoReview [Internet]. 31 maj 2011 [cytowane 23 lipiec 2024];1(2(2):148-50. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/249
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Piccioli A., Lensing A.W., Prins M.H., Falanga A., Scannapieco G.L., Ieran M., Cigolini M., Ambrosio G.B., Monreal M., Girolami A., Prandoni P.: Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J. Thromb. Haemost. 2004; 2(6): 884-889.
2. Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galie N., Pruszczyk P., Bengel F., Brady A.J., Ferreira D., Janssens U., Klepetko W., Mayer E., Remy-Jardin M., Bassand J.P., Vahanian A., Camm J., De C.R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Zamorano J.L., Andreotti F., Ascherman M., Athanassopoulos G., De S.J., Fitzmaurice D., Forster T., Heras M., Jondeau G., Kjeldsen K., Knuuti J., Lang I., Lenzen M., Lopez-Sendon J., Nihoyannopoulos P., Perez I.L., Schwehr U., Torraca L., Vachiery J.L.: Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2008; 29(18): 2276-2315.
3. Akl E.A., Vasireddi S.R., Gunukula S., Barba M., Sperati F., Terrenato I., Muti P., Schunemann H.: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst. Rev. 2011; 4: CD006649.
4. Jaff M.R., McMurtry M.S., Archer S.L., Cushman M., Goldenberg N., Goldhaber S.Z., Jenkins J.S., Kline J.A., Michaels A.D., Thistlethwaite P., Vedantham S., White R.J., Zierler B.K.: Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association. Circulation 2011 Apr 26; 123(16): 1788-1830.
5. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., Rickles F.R., Julian J.A., Haley S., Kovacs M.J., Gent M.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 2003; 349(2): 146-153.
6. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., Le M.C., Extra J.M., Cottu P., Farge D.: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch. Intern. Med. 2002; 162(15): 1729-1735.
2. Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galie N., Pruszczyk P., Bengel F., Brady A.J., Ferreira D., Janssens U., Klepetko W., Mayer E., Remy-Jardin M., Bassand J.P., Vahanian A., Camm J., De C.R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Zamorano J.L., Andreotti F., Ascherman M., Athanassopoulos G., De S.J., Fitzmaurice D., Forster T., Heras M., Jondeau G., Kjeldsen K., Knuuti J., Lang I., Lenzen M., Lopez-Sendon J., Nihoyannopoulos P., Perez I.L., Schwehr U., Torraca L., Vachiery J.L.: Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2008; 29(18): 2276-2315.
3. Akl E.A., Vasireddi S.R., Gunukula S., Barba M., Sperati F., Terrenato I., Muti P., Schunemann H.: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst. Rev. 2011; 4: CD006649.
4. Jaff M.R., McMurtry M.S., Archer S.L., Cushman M., Goldenberg N., Goldhaber S.Z., Jenkins J.S., Kline J.A., Michaels A.D., Thistlethwaite P., Vedantham S., White R.J., Zierler B.K.: Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association. Circulation 2011 Apr 26; 123(16): 1788-1830.
5. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., Rickles F.R., Julian J.A., Haley S., Kovacs M.J., Gent M.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 2003; 349(2): 146-153.
6. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., Le M.C., Extra J.M., Cottu P., Farge D.: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch. Intern. Med. 2002; 162(15): 1729-1735.